aTyr Pharma (NASDAQ:LIFE) Downgraded to Sell at StockNews.com

aTyr Pharma (NASDAQ:LIFEGet Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

A number of other research analysts also recently commented on the stock. Piper Sandler boosted their price objective on shares of aTyr Pharma from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Monday, August 15th. HC Wainwright boosted their price objective on shares of aTyr Pharma from $11.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 21st.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $2.49 on Friday. The firm’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $3.10. The company has a market cap of $71.29 million, a P/E ratio of -1.51 and a beta of 1.31. aTyr Pharma has a fifty-two week low of $2.22 and a fifty-two week high of $8.90.

aTyr Pharma (NASDAQ:LIFEGet Rating) last released its earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same period last year, the firm earned ($0.64) EPS. On average, analysts expect that aTyr Pharma will post -1.81 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

Several large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in aTyr Pharma by 14.7% in the third quarter. Dimensional Fund Advisors LP now owns 169,360 shares of the biotechnology company’s stock worth $508,000 after acquiring an additional 21,764 shares in the last quarter. Tower Research Capital LLC TRC grew its position in aTyr Pharma by 87.8% in the third quarter. Tower Research Capital LLC TRC now owns 40,965 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 19,150 shares in the last quarter. Jane Street Group LLC bought a new stake in aTyr Pharma in the second quarter worth approximately $29,000. Renaissance Technologies LLC grew its position in aTyr Pharma by 36.1% in the second quarter. Renaissance Technologies LLC now owns 150,825 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 39,970 shares in the last quarter. Finally, FMR LLC grew its position in aTyr Pharma by 0.9% in the second quarter. FMR LLC now owns 4,208,437 shares of the biotechnology company’s stock worth $11,910,000 after acquiring an additional 39,068 shares in the last quarter. 65.58% of the stock is owned by institutional investors.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Further Reading

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.